Epigenetic?s Researcher?s Enthuse Over ChromaTrap ChIP Technology
Porvair Sciences reports strong growing demand for their Chromatrap chromatin immunoprecipitation (ChIP) assay technology from academic groups and biopharmaceutical organisations involved with epigenetic research.
Stephen Knight, Sales and Marketing Director commented: "An expanding number of proven application solutions and the introduction of the Chromatrap 96 HT solid-state ChIP high throughput platform has enabled us to more than double the number of research groups using ChromaTrap assay technology during the last 12 months." He added: "We are particularly pleased by the very positive feedback from early adopters of the technology."
Brian J. Engel, a Biochemistry & Cell Biology researcher at Rice University, USA commented: "What I like most about the Chromatrap kit compared with traditional bead-based ChIP assays is the ease of use, speed and reliability. There is no worry about accidentally losing beads during washes and reducing output chromatin when using the column-based method." His colleague, Curt Warren, added: "We have found that the Chromatrap kit is quick, reliable and flexible. Saving reagents and time with this kit makes it easier and more feasible to conduct more thorough and effective IP-based experiments. With the enhanced reproducibility using Chromatrap, I would not go back to bead-based ChIP and the assay has been fully endorsed and adopted within our research team."
Professor Steve Conlan, Head of Molecular & Cell Biology at Swansea University, UK commented: "Chromatrap streamlines the complicated experimental procedure associated with chromatin-IP making it a much quicker and user-friendly assay compared with conventional bead based assays. Using this kit we obtain much more consistent data, and most importantly can use much less input sample. We have made a permanent switch to using Chromatrap for all our cell line and primary cell based assays, and fully endorse the technology." Research assistant, Dr Helen Whiteland, added: "What I like about the Chromatrap assay is the ease of use and quick method allowing me to analyse my data in the same day."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance